Skip to main content

Table 1 Paediatric cohort characteristics and outcomes

From: Lessons learned from family-centred models of treatment for children living with HIV: current approaches and future directions

Author/Date

# children on HAART

Age at initiation

Duration of follow up

CD4 at initiation

Adherence

Survival

Loss to Follow-Up

Abrams 2005 [18]

144

 

Median 19 months

(Range 2 months - 12 years)

    

Van Griensven 2008 [28]

332

Median 7.2 years

(IQR 4.5-10.4)

Median 2.0 years

(IQR 1.2-2.6)

Median 14%

(IQR 9-18%)

49%: >95% adherence

46%: >80% adherence

98% survival at 12 months

8 deaths (2.6% mortality)

12 children

(3.8%)

Eley 2004 [22]

80

Median 1.25 years

(Range .003-12.0)

  

"Most": >85% adherence

7 deaths (8.8% mortality)

4 children

(5%)

Habibu 2006 [23]*

52

   

>95% adherence

 

0 children

Lusiama 2004 [24]*

393

Median 7.5 (years)

(IQR 4.3-10.5)

Median 21.9 months

(IQR 7.5-25.9)

Median 12%

(IQR 7-18%)

 

30 deaths (8% mortality)

44 children

(9%)

Midturi 2008 [25]*

56

Mean 39.6 months

Mean 14.7 months

 

77.8% adherence

1.8% mortality

1.8%

Reddi 2007 [26]

151

Median 5.7 years

(Range 0.3-15.4)

Median 8 months

(IQR 3.5-13.5)

Median 7.4%

(IQR 2.1-13.7%)

59.6%: no missed doses

29.8%: >95% adherence

90.9% survival at 12 months

13 deaths (8.6% mortality)

0 children

Tonwe-Gold 2009 [27]

43

 

Median 12 months

(IQR 5.0-15.0)

  

2 deaths (4.9% mortality)

0 children

Van Winghem 2008 [29]

657

Median 5.5 years

(IQR 3.2-8.7)

Median 1.36 years

(IQR 0.6-2.2)

  

95.3% survival at 12 months

7 deaths (6.7% mortality)

67 children (10.2%)

  1. * Indicates that this refers to a conference abstract, rather than a published journal article
  2. Note: An empty table cell indicates none of that type of data were available in that publication